Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 9382092, 6 pages
http://dx.doi.org/10.1155/2016/9382092
Research Article

Associations of A-FABP with Anthropometric and Metabolic Indices and Inflammatory Cytokines in Obese Patients with Newly Diagnosed Type 2 Diabetes

1Department of Endocrinology, People’s Hospital of Liaocheng, Shandong 252000, China
2Department of Urology, People’s Hospital of Liaocheng, Shandong 252000, China

Received 12 June 2016; Accepted 25 September 2016

Academic Editor: Koichiro Wada

Copyright © 2016 Guifen Niu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Executive Summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association,” Circulation, vol. 133, no. 4, pp. 447–454, 2016. View at Publisher · View at Google Scholar
  2. K. M. Flegal, D. Carroll, B. K. Kit, and C. L. Ogden, “Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010,” Journal of the American Medical Association, vol. 307, no. 5, pp. 491–497, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. N. M. Maruthur, “The growing prevalence of type 2 diabetes: increased incidence or improved survival?” Current Diabetes Reports, vol. 13, no. 6, pp. 786–794, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. Scheen, “Current management strategies for coexisting diabetes mellitus and obesity,” Drugs, vol. 63, no. 12, pp. 1165–1184, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Robiou-Du-Pont, A. Bonnefond, L. Yengo et al., “Contribution of 24 obesity-associated genetic variants to insulin resistance, pancreatic beta-cell function and type 2 diabetes risk in the French population,” International Journal of Obesity, vol. 37, no. 7, pp. 980–985, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. F. Neurath and S. Finotto, “IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer,” Cytokine and Growth Factor Reviews, vol. 22, no. 2, pp. 83–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. K. M. Nieman, H. A. Kenny, C. V. Penicka et al., “Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth,” Nature Medicine, vol. 17, no. 11, pp. 1498–1503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Furuhashi, M. Furuhashi, S. Saitoh, K. Shimamoto, and T. Miura, “Fatty Acid-Binding Protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases,” Clinical Medicine Insights: Cardiology, vol. 8, pp. 23–33, 2014. View at Publisher · View at Google Scholar
  9. A. Vogel Hertzel and D. A. Bernlohr, “The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function,” Trends in Endocrinology and Metabolism, vol. 11, no. 5, pp. 175–180, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Xu, Y. Wang, J. Y. Xu et al., “Adipocyte fatty acid–binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome,” Clinical Chemistry, vol. 52, no. 3, pp. 405–413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. W. K. Tso, A. Xu, P. C. Sham et al., “Serum adipocyte fatty acid-binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort,” Diabetes Care, vol. 30, no. 10, pp. 2667–2672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. S. Hotamisligil and D. A. Bernlohr, “Metabolic functions of FABPs—mechanisms and therapeutic implications,” Nature Reviews Endocrinology, vol. 11, no. 10, pp. 592–605, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Bhushan, A. Khalyfa, K. Spruyt et al., “Fatty-acid binding protein 4 gene polymorphisms and plasma levels in children with obstructive sleep apnea,” Sleep Medicine, vol. 12, no. 7, pp. 666–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. K. T. Uysal, L. Scheja, S. M. Wiesbrock, S. Bonner-Weir, and G. S. Hotamisligil, “Improved glucose and lipid metabolism in genetically obese mice lacking aP2,” Endocrinology, vol. 141, no. 9, pp. 3388–3396, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Tuncman, E. Erbay, X. Hom et al., “A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 18, pp. 6970–6975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mankowska-Cyl, M. Krintus, P. Rajewski, and G. Sypniewska, “A-FABP and its association with atherogenic risk profile and insulin resistance in young overweight and obese women,” Biomarkers in Medicine, vol. 7, no. 5, pp. 723–730, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Terra, Y. Quintero, T. Auguet et al., “FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women,” European Journal of Endocrinology, vol. 164, no. 4, pp. 539–547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. M. Gabir, R. L. Hanson, D. Dabelea et al., “The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes,” Diabetes Care, vol. 23, no. 8, pp. 1108–1112, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  20. J. B. Boord, S. Fazio, and M. F. Linton, “Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis,” Current Opinion in Lipidology, vol. 13, no. 2, pp. 141–147, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Corripio, J.-M. Gónzalez-Clemente, J. Pérez-Sánchez et al., “Weight loss in prepubertal obese children is associated with a decrease in adipocyte fatty-acid-binding protein without changes in lipocalin-2: a 2-year longitudinal study,” European Journal of Endocrinology, vol. 163, no. 6, pp. 887–893, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J. H. Koh, Y. G. Shin, S. M. Nam, M. Y. Lee, C. H. Chung, and J. Y. Shin, “Serum adipocyte fatty acid–binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients,” Diabetes Care, vol. 32, no. 1, pp. 147–152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Furuhashi, G. Tuncman, C. Z. Görgün et al., “Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2,” Nature, vol. 447, no. 7147, pp. 959–965, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Zhou, Y. Bao, J. Lu, J. Zhou, and W. Jia, “Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone,” PLoS ONE, vol. 6, no. 10, article e27032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Roden, “Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance,” Nature Clinical Practice Endocrinology and Metabolism, vol. 2, no. 6, pp. 335–348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Mölig, M. O. Weickert, E. Ghadamgadai et al., “Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women,” European Journal of Endocrinology, vol. 157, no. 2, pp. 195–200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. Å. Sjöholm and T. Nyström, “Endothelial inflammation in insulin resistance,” The Lancet, vol. 365, no. 9459, pp. 610–612, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Furuhashi, R. Fucho, C. Z. Görgün, G. Tuncman, H. Cao, and G. S. Hotamisligil, “Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice,” The Journal of Clinical Investigation, vol. 118, no. 7, pp. 2640–2650, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Pappu, V. Ramirez-Carrozzi, and A. Sambandam, “The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases,” Immunology, vol. 134, no. 1, pp. 8–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Honkanen, J. K. Nieminen, R. Gao et al., “IL-17 immunity in human type 1 diabetes,” Journal of Immunology, vol. 185, no. 3, pp. 1959–1967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Jagannathan-Bogdan, M. E. McDonnell, H. Shin et al., “Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes,” Journal of Immunology, vol. 186, no. 2, pp. 1162–1172, 2011. View at Publisher · View at Google Scholar · View at Scopus